

Specimen ID: 148-544-6249-0

Control ID: 98331228333

Acct #: 04321410

Phone: (415) 963-4431

Rte: 00

FARMER, CHRISTOPHER W.

2846 WASHINGTON ST

SAN FRANCISCO CA 94115

(415) 596-4210

Paul D Abramson MD

450 Sutter St Ste 840

SAN FRANCISCO CA 94108



Patient Details	Specimen Details	Physician Details
DOB: 10/12/1974	Date collected: 05/28/2025 0745 Local	Ordering: P ABRAMSON
Age(y/m/d): 050/07/16	Date received: 05/28/2025	Referring:
Gender: M	Date entered: 05/28/2025	ID: 1417977315
Patient ID: 703464722464769	Date reported: 06/04/2025 1010 ET	NPI: 1417977315

General Comments & Additional Information

Alternate Control Number: 983312283336737

Alternate Patient ID: 703464722464769

Total Volume: Not Provided

Fasting: Yes

Ordered Items

NMR LipoProfile+Lipids+IR+Gph; Celiac Disease Comprehensive; Vitamin D, 25-Hydroxy; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Iron and TIBC; DHT, Free, LCMS/Dialysis; Free Androgen Index (FAI); Hgb A1c with eAG Estimation; PSA Total (Reflex To Free); Dihydrotestosterone; Mercury, Serum/Plasma; Hep B Surface Ab, Qual; Measles Antibodies, IgG; C-Reactive Protein, Cardiac; TSH w/Reflex; Methylmalonic Acid, Serum; Uric Acid; Sedimentation Rate-Westergren; Insulin; Ferritin; Magnesium, RBC; Apolipoprotein B

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
NMR LipoProfile+Lipids+IR+Gph					
LDL Particle Number					01
LDL-P ^A	1246	High	nmol/L	<1000	01
		Low		< 1000	
		Moderate		1000 - 1299	
		Borderline-High		1300 - 1599	
		High		1600 - 2000	
		Very High		> 2000	
Lipids					01
LDL-C (NIH Calc)	103	High	mg/dL	0-99	01
		Optimal		< 100	
		Above optimal		100 - 129	
		Borderline		130 - 159	
		High		160 - 189	
		Very high		> 189	
HDL-C ^A	40		mg/dL	>39	01
Triglycerides ^A	160	High	mg/dL	0-149	01
Cholesterol, Total ^A	171		mg/dL	100-199	01
LDL and HDL Particles					01
HDL-P (Total) ^A	25.8	Low	umol/L	>=30.5	01
Small LDL-P ^A	531	High	nmol/L	<=527	01
LDL Size ^A	21.3		nm	>20.5	01

** INTERPRETATIVE INFORMATION**					
PARTICLE CONCENTRATION AND SIZE					
<--Lower CVD Risk Higher CVD Risk-->					
LDL AND HDL PARTICLES	Percentile in Reference Population				
HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839

Patient Report



Patient: FARMER, CHRISTOPHER W.

DOB: 10/12/1974

Patient ID: 703464722464769

Control ID: 98331228333

Specimen ID: 148-544-6249-0

Date collected: 05/28/2025 0745 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
LDL Size	<-Large (Pattern A)->	<-Small (Pattern B)->			
	23.0 20.6	20.5 19.0			

Comment: 01
Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance/Diab. Risk 01

Large VLDL-P ^A 4.7 High nmol/L <=2.7 01

Small LDL-P ^A 531 High nmol/L <=527 01

Large HDL-P ^A 4.2 Low umol/L >=4.8 01

VLDL Size ^A 47.7 High nm <=46.6 01

LDL Size ^A 21.3 nm >=20.8 01

HDL Size ^A 8.8 Low nm >=9.2 01

Insulin Resistance Score 01

LP-IR Score ^A 55 High <=45 01

INSULIN RESISTANCE / DIABETES RISK MARKERS

<--Insulin Sensitive Insulin Resistant-->

Percentile in Reference Population

	Low	25th	50th	75th	High
Large VLDL-P	<0.9	0.9	2.7	6.9	>6.9
Small LDL-P	<117	117	527	839	>839
Large HDL-P	High	75th	50th	25th	Low
	>7.3	7.3	4.8	3.1	<3.1
VLDL Size	Small	25th	50th	75th	Large
	<42.4	42.4	46.6	52.5	>52.5
LDL Size	Large	75th	50th	25th	Small
	>21.2	21.2	20.8	20.4	<20.4
HDL Size	Large	75th	50th	25th	Small
	>9.6	9.6	9.2	8.9	<8.9
Insulin Resistance Score					
LP-IR SCORE	Low	25th	50th	75th	High
	<27	27	45	63	>63

Comment: 01
LP-IR Score is inaccurate if patient is non-fasting.
The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

PDF . 01

Historical Reporting Comment: 01

Collection Date	LDL-P	LDL-C
05/28/2025	1246	103
01/02/2024	909	98

Patient Report



Patient: FARMER, CHRISTOPHER W.

DOB: 10/12/1974

Patient ID: 703464722464769

Control ID: 98331228333

Specimen ID: 148-544-6249-0

Date collected: 05/28/2025 0745 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Celiac Disease Comprehensive

Deamidated Gliadin Abs, IgA	11		units	0-19	01
		Negative		0 - 19	
		Weak Positive		20 - 30	
		Moderate to Strong Positive		>30	
Deamidated Gliadin Abs, IgG	7		units	0-19	01
		Negative		0 - 19	
		Weak Positive		20 - 30	
		Moderate to Strong Positive		>30	
t-Transglutaminase (tTG) IgA	<2		U/mL	0-3	01
		Negative		0 - 3	
		Weak Positive		4 - 10	
		Positive		>10	
Tissue Transglutaminase (tTG) has been identified as the endomysial antigen. Studies have demonstrated that endomysial IgA antibodies have over 99% specificity for gluten sensitive enteropathy.					
t-Transglutaminase (tTG) IgG	5		U/mL	0-5	01
		Negative		0 - 5	
		Weak Positive		6 - 9	
		Positive		>9	
Endomysial Antibody IgA	Negative			Negative	01
Immunoglobulin A, Qn, Serum	370		mg/dL	90-386	02

Vitamin D, 25-Hydroxy

	63.0		ng/mL	30.0-100.0	02
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).					
1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.					
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.					

Patient Report



Patient: FARMER, CHRISTOPHER W.

DOB: 10/12/1974

Patient ID: 703464722464769

Control ID: 98331228333

Specimen ID: 148-544-6249-0

Date collected: 05/28/2025 0745 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

CBC With Differential/Platelet

WBC	6.1		x10E3/uL	3.4-10.8	02
RBC	4.52		x10E6/uL	4.14-5.80	02
Hemoglobin	14.8		g/dL	13.0-17.7	02
Hematocrit	44.1		%	37.5-51.0	02
MCV	98	High	fL	79-97	02
MCH	32.7		pg	26.6-33.0	02
MCHC	33.6		g/dL	31.5-35.7	02
RDW	12.5		%	11.6-15.4	02
Platelets	226		x10E3/uL	150-450	02
Neutrophils	35		%	Not Estab.	02
Lymphs	51		%	Not Estab.	02
Monocytes	9		%	Not Estab.	02
Eos	4		%	Not Estab.	02
Basos	1		%	Not Estab.	02
Neutrophils (Absolute)	2.2		x10E3/uL	1.4-7.0	02
Lymphs (Absolute)	3.1		x10E3/uL	0.7-3.1	02
Monocytes (Absolute)	0.5		x10E3/uL	0.1-0.9	02
Eos (Absolute)	0.2		x10E3/uL	0.0-0.4	02
Baso (Absolute)	0.0		x10E3/uL	0.0-0.2	02
Immature Granulocytes	0		%	Not Estab.	02
Immature Grans (Abs)	0.0		x10E3/uL	0.0-0.1	02

Comp. Metabolic Panel (14)

Glucose	87		mg/dL	70-99	02
BUN	20		mg/dL	6-24	02
Creatinine	0.78		mg/dL	0.76-1.27	02
eGFR	109		mL/min/1.73	>59	02
BUN/Creatinine Ratio	26	High		9-20	02
Sodium	143		mmol/L	134-144	02
Potassium	4.1		mmol/L	3.5-5.2	02
Chloride	106		mmol/L	96-106	02
Carbon Dioxide, Total	23		mmol/L	20-29	02
Calcium	9.5		mg/dL	8.7-10.2	02
Protein, Total	7.0		g/dL	6.0-8.5	02
Albumin	4.7		g/dL	4.1-5.1	02
Globulin, Total	2.3		g/dL	1.5-4.5	02
Bilirubin, Total	0.3		mg/dL	0.0-1.2	02
Alkaline Phosphatase	67		IU/L	44-121	02

Patient Report



Patient: FARMER, CHRISTOPHER W.

DOB: 10/12/1974

Patient ID: 703464722464769

Control ID: 98331228333

Specimen ID: 148-544-6249-0

Date collected: 05/28/2025 0745 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
AST (SGOT)	23		IU/L	0-40	02
ALT (SGPT)	19		IU/L	0-44	02
Iron and TIBC					
Iron Bind.Cap. (TIBC)	243	Low	ug/dL	250-450	
UIBC	153		ug/dL	111-343	02
Iron	90		ug/dL	38-169	02
Iron Saturation	37		%	15-55	
DHT, Free, LCMS/Dialysis					
Dihydrotestosterone	11	Low	ng/dL		03
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.					
Reference Range:					
Adult Male: 30 - 85					
DHT, Percent Free Dialysis	0.76		%		03
This test was developed and the performance characteristics were validated by LabCorp. It has not been cleared or approved by the Food and Drug Administration.					
Reference Range:					
<18y: Not Established					
Adult Males: 0.54 - 2.58					
DHT, Free	0.84	Low	pg/mL		03
Reference Range:					
<18y: Not Established					
Adult Males: 2.30 - 11.60					
Free Androgen Index (FAI)					
Testosterone	864		ng/dL	264-916	02
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Sex Horm Binding Glob, Serum	57.8		nmol/L	19.3-76.4	02
Free Androgen Index	51.9			18.0-82.0	
Hgb A1c with eAG Estimation					
Hemoglobin A1c	5.5		%	4.8-5.6	02
Please Note:					
Prediabetes: 5.7 - 6.4					
Diabetes: >6.4					
Glycemic control for adults with diabetes: <7.0					
Estim. Avg Glu (eAG)	111		mg/dL		
PSA Total (Reflex To Free)					
Prostate Specific Ag	0.5		ng/mL	0.0-4.0	02
Roche ECLIA methodology.					
According to the American Urological Association, Serum PSA should					

Patient Report



Patient: FARMER, CHRISTOPHER W.
DOB: 10/12/1974

Patient ID: 703464722464769

Control ID: 98331228333

Specimen ID: 148-544-6249-0
Date collected: 05/28/2025 0745 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.					
Reflex Criteria	The percent free PSA is performed on a reflex basis only when the total PSA is between 4.0 and 10.0 ng/mL.				02
Mercury, Serum/Plasma					
Mercury	<5		ng/ml	<5	04
Urine is the preferred specimen for monitoring mercury exposure.					
Mercury analysis performed by inductively coupled plasma / mass spectrometry (ICP/MS).					
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.					
Hep B Surface Ab, Qual	Equivocal				02
Non Reactive: Not immune to HBV infection.					
Equivocal: Unable to determine if anti-HBs is present at levels consistent with immunity.					
Reactive: Anti-HBs concentration detected at greater than 10 mIU/mL. Individual is considered to be immune to infection with HBV.					
Verified by repeat analysis					
Measles Antibodies, IgG	14.1	Low	AU/mL	Immune >16.4	02
A second sample should be collected and tested no less than 2-4 weeks.					
Negative <13.5					
Equivocal 13.5 - 16.4					
Positive >16.4					
Presence of antibodies to Rubeola is presumptive evidence of immunity except when acute infection is suspected.					
C-Reactive Protein, Cardiac	0.61		mg/L	0.00-3.00	02
Relative Risk for Future Cardiovascular Event					
Low <1.00					
Average 1.00 - 3.00					
High >3.00					
TSH w/Reflex					
TSH	0.901		uIU/mL	0.450-4.500	02

Patient: FARMER, CHRISTOPHER W.
DOB: 10/12/1974

Patient ID: 703464722464769

Control ID: 98331228333

Specimen ID: 148-544-6249-0
Date collected: 05/28/2025 0745 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Methylmalonic Acid, Serum ^A	87		nmol/L	0-378	01
Uric Acid	6.1		mg/dL	3.8-8.4	02
	Therapeutic target for gout patients: <6.0				
Sedimentation Rate-Westergren	2		mm/hr	0-30	02
Insulin	15.6		uIU/mL	2.6-24.9	02
Ferritin	201		ng/mL	30-400	02
Magnesium, RBC ^A	5.3		mg/dL	3.7-7.0	01
Apolipoprotein B	77		mg/dL	<90	02
			Desirable	< 90	
			Borderline High	90 - 99	
			High	100 - 130	
			Very High	>130	

	ASCVD RISK CATEGORY		THERAPEUTIC TARGET APO B (mg/dL)		
	Very High Risk		<80 (if extreme risk <70)		
	High Risk		<90		
	Moderate Risk		<90		

Comments:

^A This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

01	BN	Labcorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
02	SO	Labcorp San Diego 13112 Evening Creek Dr So Ste 200, San Diego, CA 92128-4108	Dir: Earle Collum, Jr, MD
03	ES	Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358	Dir: Brian Poirier, MD
04	MX	MedTox Laboratories Inc 402 W County Road D, St Paul, MN 55112-3522	Dir: Karla Walker, PhrmD

For inquiries, the physician may contact **Branch: 800-888-1113 Lab: 800-762-4344**

Specimen Number 148-544-6249-0	Patient ID 703464722464769	Account Number 04321410	Account Phone (415) 963-4431	Account Fax (415) 963-4431
Patient Last Name FARMER	Patient First Name CHRISTOPHER	Account Address Paul D Abramson MD 450 Sutter St Ste 840 SAN FRANCISCO, CA 94108		
Age 50	Date of Birth 10/12/1974			
Control Number 98331228333	NPI 1417977315			
Date Collected 05/28/2025	Date Entered 05/28/2025	Date and Time Reported 05/30/2025 08:49 PM ET	Physician ID & Name 1417977315 - ABRAMSON, P	Page Number 1 of 2

❖ **NMR LipoProfile® test**

Reference Interval¹

	Percentile ¹	20th	50th	80th	95th	
	nmol/L	Low	Moderate	Borderline High	High	Very High
LDL-P (LDL Particle Number)	1246	< 1000	1000 - 1299	1300 - 1599	1600 - 2000	> 2000


1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

❖ **Lipids**

	mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
LDL-C (calculated)	103	< 100	100 - 129	130 - 159	160 - 189	≥ 190

HDL-C	40	Triglycerides	160	Total Cholesterol	171
Desirable ≥ 40		Desirable < 150		Desirable < 200	

Historical Reporting



❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

Issued or Pending
PATENTS

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number 34D0655059

Specimen Number 148-544-6249-0	Patient ID 703464722464769	Account Number 04321410	Account Phone (415) 963-4431	Account Fax (415) 963-4431
Patient Last Name FARMER	Patient First Name CHRISTOPHER	Account Address Paul D Abramson MD 450 Sutter St Ste 840 SAN FRANCISCO, CA 94108		
Age 50	Date of Birth 10/12/1974			
Sex M	Fasting YES			
Control Number 98331228333	NPI 1417977315			
Date Collected 05/28/2025	Date Entered 05/28/2025	Date and Time Reported 05/30/2025 08:49 PM ET	Physician ID & Name 1417977315 - ABRAMSON, P	Page Number 2 of 2

PARTICLE CONCENTRATION AND SIZE

❖ LDL and HDL Particles		Lower CVD Risk ← Higher CVD Risk →				
		Percentile in Reference Population ^①				
	μmol/L	high	75th	50th	25th	low
HDL-P (total)	25.8		34.9	30.5	26.7	
	nmol/L	low	25th	50th	75th	high
SMALL LDL-P	531		117	527	839	
	nm					
LDL SIZE	21.3	23.0	Large (Pattern A)	20.6	20.5	Small (Pattern B) 19.0
Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.						
LipoProtein Markers Associated with Insulin Resistance & Diabetes Risk ^{②③}		Insulin Sensitive ← Insulin Resistant →				
		Percentile in Reference Population ^①				
	nmol/L	low	25th	50th	75th	high
LARGE VLDL-P	4.7		0.9	2.7	6.9	
	nmol/L	low	25th	50th	75th	high
SMALL LDL-P	531		117	527	839	
	μmol/L	high	75th	50th	25th	low
LARGE HDL-P	4.2		7.3	4.8	3.1	
	nm	small	25th	50th	75th	large
VLDL SIZE	47.7		42.4	46.6	52.5	
	nm	large	75th	50th	25th	small
LDL SIZE	21.3		21.2	20.8	20.4	
	nm	large	75th	50th	25th	small
HDL SIZE	8.8		9.6	9.2	8.9	
Insulin Resistance Score						
	0-100	insulin sensitive	25th	50th	75th	insulin resistant
LP-IR SCORE**	55		27	45	63	

** The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. Neither the LP-IR score nor the subclasses listed above have been cleared by the US Food and Drug Administration.

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.